Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Oliguria in Children
← New Search

Oliguria in Children

Pediatric oliguria definition, common causes, red flags, and initial workup for medical students and clinicians.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is intended for educational purposes and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare provider based on the individual patient's condition, medical history, and current clinical context. The information provided is current as of the last update but medical knowledge is constantly evolving.

Overview

  • Definition: Oliguria in a child is defined as a urine output of less than 1 mL/kg/hour for infants and young children, or less than 0.5 mL/kg/hour for older children and adolescents, sustained for a period of 6-12 hours. Anuria is typically defined as urine output less than 0.2-0.3 mL/kg/hour or complete absence of urine output. Oliguria is a cardinal sign of acute kidney injury (AKI) in children.
  • Epidemiology: AKI, often presenting with oliguria, is common in critically ill children, affecting approximately 10-30% of pediatric intensive care unit (PICU) admissions. Its incidence has increased due to improved recognition and the survival of children with complex medical conditions.
  • Classification:
    • Prerenal AKI: Caused by decreased renal perfusion without direct parenchymal injury. This is the most common cause of AKI in children.
    • Intrinsic Renal AKI: Results from direct damage to the kidney parenchyma (glomeruli, tubules, interstitium, or vasculature).
    • Postrenal AKI (Obstructive Uropathy): Due to obstruction of urine flow anywhere from the renal pelvis to the urethra.

Pathophysiology

  • Mechanism:
    • Prerenal: Inadequate blood flow to the kidneys leads to decreased glomerular filtration. Common causes include hypovolemia (dehydration, hemorrhage, burns, sepsis), decreased effective circulating volume (heart failure, nephrotic syndrome, cirrhosis), systemic vasodilation (sepsis, anaphylaxis), and renal vasoconstriction (NSAIDs, ACE inhibitors, calcineurin inhibitors, renovascular disease). The kidney initially attempts to preserve GFR through autoregulation.
    • Intrinsic Renal:
      • Acute Tubular Necrosis (ATN): Most common intrinsic cause in children, often due to prolonged severe ischemia (e.g., prerenal causes progressing) or nephrotoxins (e.g., aminoglycosides, vancomycin, cisplatin, NSAIDs, IV contrast). Damage to tubular cells impairs reabsorption and secretion, leading to decreased urine output.
      • Glomerulonephritis: Inflammation of the glomeruli, reducing filtration surface area. Examples: post-streptococcal glomerulonephritis, lupus nephritis, IgA nephropathy, Henoch-Schönlein purpura nephritis.
      • Acute Interstitial Nephritis (AIN): Allergic or immune-mediated inflammation of the renal interstitium, commonly drug-induced (e.g., penicillins, NSAIDs).
      • Vascular: Renal artery or vein thrombosis, hemolytic uremic syndrome (HUS), disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), vasculitis.
    • Postrenal: Mechanical obstruction of urine outflow. Causes include posterior urethral valves (PUV) in males, ureteropelvic junction (UPJ) obstruction, stones, tumors, neurogenic bladder, or external compression. Leads to increased intratubular pressure, opposing glomerular filtration.
  • Risk Factors:
    • Systemic: Sepsis, shock, hypovolemia, dehydration, cardiac dysfunction (heart failure, congenital heart disease with surgery), liver failure, severe burns, rhabdomyolysis, tumor lysis syndrome.
    • Renal/Urinary Tract: Congenital anomalies of the kidney and urinary tract (CAKUT), pre-existing chronic kidney disease (CKD), solitary kidney.
    • Medication-Related: Nephrotoxic drugs (aminoglycosides, NSAIDs, ACE inhibitors/ARBs, contrast media, certain chemotherapy agents).
    • Surgical Procedures: Cardiopulmonary bypass, major abdominal or urological surgery.
  • Protective Factors:
    • Maintaining adequate hydration and euvolemia.
    • Avoiding nephrotoxic medications when possible or using them judiciously with close monitoring.
    • Prompt recognition and aggressive treatment of conditions predisposing to AKI (e.g., sepsis, shock).
    • Optimizing cardiac function and systemic perfusion.

Clinical Presentation

Signs and Symptoms

  • Cardinal Features:
    • Significantly decreased urine output (parents may report fewer wet diapers, less frequent urination, or smaller urine volume).
    • Weight gain (if fluid overloaded).
    • Lethargy, irritability, poor feeding (especially in infants).
  • Early Signs:
    • Decreased frequency of urination.
    • Mild periorbital or sacral edema.
    • Thirst (if hypovolemic).
    • Generalized malaise.
  • Advanced Signs:
    • Anuria.
    • Generalized edema (anasarca).
    • Signs of fluid overload: pulmonary edema (tachypnea, dyspnea, crackles, increased work of breathing), hypertension, jugular venous distension (in older children).
    • Signs of uremia: severe lethargy, confusion, seizures, nausea, vomiting, metallic taste in mouth, anorexia.
    • Symptoms related to electrolyte derangements (e.g., muscle weakness, cardiac arrhythmias from hyperkalemia).
  • Atypical Presentations:
    • Non-oliguric AKI (less common but possible, particularly in nephrotoxic drug-induced injury, where urine output is preserved but GFR decreases).
    • Oliguria masked by high insensible losses (e.g., fever, burns), making volume status assessment challenging.

Physical Examination

  • Inspection:
    • General appearance: Alertness, activity level, signs of distress (respiratory, pain).
    • Skin: Pallor (anemia), cyanosis, evidence of rash (vasculitis, HUS), turgor, mucous membrane moisture, presence of edema (periorbital, sacral, pedal, generalized).
    • Head and Neck: Sunken fontanelle (infants, dehydration), JVD (fluid overload).
    • Chest: Increased work of breathing, accessory muscle use, retractions, signs of pulmonary edema.
    • Abdomen: Distension, scars (prior surgery), ascites.
    • Extremities: Peripheral edema, capillary refill time.
  • Palpation:
    • Peripheral pulses: Rate, rhythm, quality (bounding, thready).
    • Capillary refill time: Prolonged (>2 seconds) indicates poor perfusion.
    • Skin temperature: Cool extremities (poor perfusion).
    • Abdomen: Palpable bladder (suggests obstruction), kidney size/tenderness (enlarged kidneys can suggest hydronephrosis, polycystic kidney disease, or inflammation).
    • Hepatomegaly: May indicate fluid overload or heart failure.
  • Special Tests:
    • Vital signs: Blood pressure (hypotension in shock, hypertension in fluid overload or intrinsic renal disease), heart rate, respiratory rate. Orthostatic vital signs if clinically indicated and patient stable enough.
    • Auscultation: Heart sounds (murmurs, gallops), lung sounds (crackles, wheezes).

Diagnostic Approach

History Taking

  • Key Questions:
    • Onset and Duration: When was the oliguria first noted? How significant is the decrease? Any periods of anuria?
    • Preceding Illnesses: Recent vomiting, diarrhea, fever, decreased oral intake (suggesting dehydration)? Signs of infection (sepsis)?
    • Medications: Any new medications, especially NSAIDs, antibiotics (aminoglycosides, vancomycin), ACE inhibitors/ARBs, diuretics, chemotherapy, or contrast media exposure?
    • Fluid Balance: Estimated fluid intake and output (insensible losses, emesis, diarrhea).
    • Symptoms of Fluid Overload: Weight gain, swelling, difficulty breathing.
    • Symptoms of Uremia: Nausea, vomiting, lethargy, confusion, seizures.
    • Urinary Symptoms: Dysuria, hematuria, frequency, urgency, straining to void, weak stream (suggesting obstruction or UTI). History of UTIs?
    • Past Medical History: Previous kidney disease, congenital anomalies of the urinary tract (e.g., posterior urethral valves, hydronephrosis), heart disease, chronic medical conditions.
    • Family History: Kidney disease, deafness (Alport syndrome), polycystic kidney disease.
    • Social History: Access to clean water, socioeconomic factors affecting hydration.
  • Red Flags:
    • Sudden onset anuria.
    • Signs of severe fluid overload (acute respiratory distress, severe hypertension).
    • Severe electrolyte disturbances (e.g., hyperkalemia with EKG changes).
    • Altered mental status or seizures.
    • Evidence of severe systemic illness (e.g., sepsis, multi-organ dysfunction).

Laboratory Tests

  • First-Line:
    • Urine Output Measurement: Strict monitoring of urine output (mL/kg/hour) is paramount. A Foley catheter may be necessary for accurate measurement in acutely ill children.
    • Urinalysis:
      • Specific Gravity: High (>1.020) suggests prerenal azotemia (concentrated urine); low (<1.010) suggests intrinsic tubular damage (inability to concentrate).
      • Proteinuria: Suggests glomerular or tubular damage.
      • Hematuria: May indicate glomerular disease, stone, or trauma.
      • Microscopy:
        • Cellular casts: Red blood cell casts (glomerulonephritis), white blood cell casts (AIN, pyelonephritis), granular or muddy brown casts (ATN).
        • Renal tubular epithelial cells: ATN.
        • Crystals: Suggests crystal nephropathy (e.g., oxalate, uric acid).
    • Serum Electrolytes: Sodium, potassium (hyperkalemia is a life-threatening complication), chloride, bicarbonate (metabolic acidosis is common).
    • BUN and Creatinine: Elevated levels indicate decreased GFR. Creatinine is a more specific marker of renal function. Trends are more important than single values.
    • Complete Blood Count (CBC): Anemia (CKD, HUS), leukocytosis (infection, inflammation), thrombocytopenia (HUS, DIC).
    • Blood Gas (Arterial or Venous): To assess acid-base status (metabolic acidosis common).
    • Blood Glucose: Essential as hypoglycemia can mimic uremia and hyperglycemia can cause osmotic diuresis/dehydration.
    • Calcium and Phosphorus: Hypocalcemia and hyperphosphatemia are common in severe AKI/CKD.
  • Confirmatory:
    • Urine Electrolytes and Osmolality:
      • Fractional Excretion of Sodium (FENa): $$FENa = \frac{Urine \: Na \times Plasma \: Cr}{Plasma \: Na \times Urine \: Cr} \times 100$$
        • Prerenal AKI: FENa <1% (often <0.5% in neonates/infants) and Urine Na <20 mmol/L, Urine Osmolality >500 mOsm/kg.
        • Intrinsic AKI (ATN): FENa >2% and Urine Na >40 mmol/L, Urine Osmolality <350 mOsm/kg.
        • Note: FENa can be misleading in patients on diuretics or with pre-existing CKD.
      • Fractional Excretion of Urea (FEUrea): Useful in patients on diuretics. FEUrea <35% suggests prerenal.
    • Specific Markers for Intrinsic Disease:
      • Complement levels (C3, C4): Reduced in post-streptococcal GN, lupus nephritis.
      • ANCA, ANA, anti-GBM antibodies: For vasculitis, lupus, Goodpasture syndrome.
      • ASO titer, anti-DNase B: For post-streptococcal GN.
      • ADAMTS13 activity: For TTP.
      • Shiga toxin testing: For STEC-HUS.
    • Novel Biomarkers (Research/Emerging): Neutrophil gelatinase-associated lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Interleukin-18 (IL-18). These can detect kidney injury earlier than creatinine but are not yet routinely used in clinical practice.
  • Monitoring:
    • Daily BUN, Creatinine, Electrolytes (Na, K, Cl, HCO3, Ca, PO4).
    • Strict fluid balance charts (input/output, daily weight).
    • Blood pressure.

Imaging

  • Recommended:
    • Renal and Bladder Ultrasound with Doppler: First-line imaging.
      • Assess kidney size, echogenicity, presence of hydronephrosis (suggests obstruction).
      • Evaluate bladder for distension, wall thickening, or mass.
      • Doppler can assess renal blood flow and rule out renal artery/vein thrombosis.
      • Also useful for detecting congenital anomalies (e.g., multicystic dysplastic kidney).
  • Advanced:
    • Voiding Cystourethrogram (VCUG): Indicated if suspicion of vesicoureteral reflux (VUR) or posterior urethral valves (PUV) after initial stabilization.
    • Dimercaptosuccinic acid (DMSA) scan: To assess for renal scarring or differential renal function, typically after initial AKI resolution.
    • CT scan of abdomen/pelvis: Rarely needed for AKI diagnosis. May be considered for complex anatomy, renal masses, or trauma, especially when ultrasound is inconclusive. Avoid contrast if possible in AKI.
    • MRI (Magnetic Resonance Imaging): Similar indications to CT, but without ionizing radiation. Avoid gadolinium-based contrast in severe AKI due to risk of nephrogenic systemic fibrosis.
    • Renal Biopsy: Considered for intrinsic renal disease if the diagnosis is unclear after non-invasive tests, or if there is rapid progression of disease (e.g., rapidly progressive glomerulonephritis) requiring specific immunosuppressive therapy.

Management

Acute Management

  • Immediate:
    • Assess airway, breathing, circulation (ABCs).
    • Evaluate hemodynamic status and volume status (hypovolemic, euvolemic, hypervolemic).
  • Stabilization:
    • Treat Underlying Cause:
      • Hypovolemia: Administer intravenous isotonic crystalloids (e.g., 0.9% NaCl) 10-20 mL/kg boluses, reassess clinical response (improved perfusion, urine output). Repeat as needed. Goal is to restore effective circulating volume. Caution: Avoid over-resuscitation in patients with normal volume status or risk of fluid overload.
      • Sepsis/Shock: Early fluid resuscitation, vasopressors as needed, antibiotics.
      • Obstruction: Urinary catheterization (if bladder obstruction) or nephrostomy tube/stent placement (if upper tract obstruction). Urgent urology consultation.
      • Nephrotoxic Drugs: Discontinue offending agents immediately.
    • Fluid Management:
      • Fluid Restriction: If euvolemic or hypervolemic, restrict fluids to maintenance requirements + ongoing losses (e.g., 300-400 mL/m2/day + previous 24hr urine output for older children, or calculated maintenance minus 1/3 to 1/2 for younger children/infants).
      • Diuretics: If fluid overload despite fluid restriction, a trial of loop diuretics (e.g., Furosemide 1-2 mg/kg IV, maximum 6 mg/kg/dose or 10 mg/kg/day, repeated q6-12h). A "furosemide stress test" (1-1.5 mg/kg IV; urine output >1 mL/kg/hr over 2h may predict recovery of AKI and avoid RRT) can be considered. If no response to maximal diuretic therapy, consider renal replacement therapy (RRT).
    • Electrolyte and Acid-Base Management:
      • Hyperkalemia: Life-threatening emergency.
        • Cardiac Stabilization: Calcium gluconate 10% 0.5-1 mL/kg IV over 5-10 minutes (max 10 mL) to stabilize cardiac membranes.
        • Intracellular Shift: Insulin (0.1 U/kg IV) with glucose (0.5 g/kg IV), albuterol (nebulized 2.5-5 mg for >20 kg, 0.15 mg/kg for <20 kg). Sodium bicarbonate (1-2 mEq/kg IV over 5-10 min if acidosis).
        • Potassium Removal: Sodium polystyrene sulfonate (Kayexalate) 0.5-1 g/kg PO/PR. If severe or refractory, urgent RRT.
      • Metabolic Acidosis: Sodium bicarbonate (1-2 mEq/kg IV) if severe (pH <7.20 or HCO3 <10 mEq/L) and symptomatic.
      • Hyperphosphatemia: Phosphate binders (calcium carbonate, sevelamer).
      • Hypocalcemia: Calcium supplementation (IV or PO) if symptomatic.
    • Nutrition: Provide adequate caloric intake (enteral feeding preferred) while managing fluid and electrolyte status. Protein restriction may be necessary if severe uremia.
  • Emergency:
    • Indications for Renal Replacement Therapy (RRT - Dialysis):
      • Severe fluid overload refractory to diuretics causing respiratory distress.
      • Severe hyperkalemia refractory to medical management.
      • Severe metabolic acidosis refractory to medical management.
      • Uremic encephalopathy, seizures, or pericarditis.
      • Refractory hypertension.
      • Certain intoxications (e.g., methanol, ethylene glycol, salicylates, lithium, some drug overdoses).
    • Types of RRT: Peritoneal dialysis (PD) is often preferred in children for its gentle nature and ease of access. Hemodialysis (HD) or Continuous Renal Replacement Therapy (CRRT) may be used, especially in critically ill or unstable patients.

Chronic Management

  • Pharmacological:
    • Management of underlying cause (e.g., immunosuppressants for glomerulonephritis, antibiotics for recurrent UTIs).
    • Medications to manage complications of AKI/CKD: Antihypertensives (ACE inhibitors/ARBs if not contraindicated by AKI, calcium channel blockers), phosphate binders, active vitamin D analogs (calcitriol), erythropoiesis-stimulating agents (ESAs) for anemia.
  • Non-pharmacological:
    • Dietary modifications: Protein, sodium, potassium, and phosphorus restriction as needed based on renal function and serum levels.
    • Fluid management education for family.
    • Regular follow-up with pediatric nephrology.
  • Monitoring:
    • Regular assessment of growth and development.
    • Monitoring of renal function (BUN, Cr, eGFR), electrolytes, acid-base balance, blood pressure.
    • Monitoring for progression of kidney disease and associated complications (anemia, bone disease).
    • Urine studies (proteinuria, urinalysis) as indicated.

Treatment Algorithms

  • First-Line:
    1. Assess and stabilize ABCs.
    2. Determine volume status: Is the child hypovolemic, euvolemic, or hypervolemic?
    3. Identify and treat underlying cause:
      • If hypovolemic: Fluid resuscitation with isotonic crystalloids (10-20 mL/kg boluses).
      • If obstructive: Relieve obstruction (catheterization, urology consult).
      • If nephrotoxic: Discontinue offending agent.
      • If sepsis: Early resuscitation, antibiotics.
    4. Provide supportive care: Strict fluid balance, daily weights, monitor electrolytes, acid-base status.
  • Second-Line:
    1. If fluid overloaded (euvolemic/hypervolemic): Fluid restriction. If persistent, trial of loop diuretics (Furosemide).
    2. Manage specific electrolyte abnormalities: Prompt treatment of hyperkalemia, hyperphosphatemia, acidosis.
    3. Specific therapies for intrinsic kidney diseases: E.g., steroids, immunosuppressants for glomerulonephritis.
  • Refractory Cases:
    1. Consider Renal Replacement Therapy (RRT): If life-threatening complications are refractory to medical management (e.g., severe fluid overload, hyperkalemia, acidosis, uremic encephalopathy).
    2. Consult pediatric nephrology early.

Complications

  • Common:
    • Fluid overload leading to peripheral and pulmonary edema.
    • Hypertension.
    • Electrolyte disturbances: Hyperkalemia, hyperphosphatemia, hypocalcemia, hyponatremia.
    • Metabolic acidosis.
  • Serious:
    • Acute respiratory failure due to pulmonary edema.
    • Cardiac arrhythmias (especially from hyperkalemia).
    • Uremic encephalopathy, seizures, coma.
    • Cardiac tamponade (uremic pericarditis).
    • Severe hypertension leading to hypertensive encephalopathy or stroke.
    • Progression to chronic kidney disease (CKD) or end-stage renal disease (ESRD).
    • Death.
  • Long-term:
    • Increased risk of CKD progression.
    • Growth failure and malnutrition.
    • Anemia.
    • Bone disease (renal osteodystrophy).
    • Neurocognitive impairment.
    • Chronic hypertension.
    • Increased morbidity and mortality from future illnesses.

Prognosis

  • Factors Affecting Outcome:
    • Etiology of AKI: Prerenal AKI generally has the best prognosis if corrected promptly. Intrinsic AKI (especially ATN) has a more variable prognosis. Postrenal AKI prognosis depends on the duration and completeness of obstruction relief and any underlying renal damage.
    • Severity of AKI: Classified by KDIGO criteria (Stage 1, 2, 3 based on creatinine rise and urine output). More severe stages, longer duration of oliguria/anuria, and need for RRT are associated with worse outcomes.
    • Underlying Disease: Patients with sepsis, multi-organ failure, or severe congenital anomalies have a higher mortality rate.
    • Age: Neonates and very young infants can be particularly vulnerable.
    • Timeliness of Intervention: Early diagnosis and appropriate management improve prognosis.
  • Survival: Varies widely depending on the cause and severity. Mortality rates for pediatric AKI can range from <10% for mild cases to >50% in critically ill children requiring RRT with multi-organ failure.
  • Quality of Life: Even after recovery from AKI, children may have a significant long-term impact on renal function, growth, neurocognitive development, and overall quality of life, especially if they develop CKD. A significant proportion (up to 20-30% of survivors of severe AKI) may develop new or worsened CKD.

Prevention

  • Primary Prevention: Aimed at preventing the initial occurrence of AKI.
    • Maintain Euvolemia: Ensure adequate hydration, especially during illness (e.g., vomiting, diarrhea, fever) or exercise.
    • Judicious Use of Nephrotoxic Drugs: Avoid unnecessary use, use lowest effective dose, monitor drug levels, adjust dosing for renal function. Be cautious with NSAIDs, especially in dehydrated children.
    • Early Recognition and Management of Systemic Conditions: Promptly treat sepsis, shock, heart failure, and conditions leading to severe dehydration.
    • Pre-hydration for Procedures: Consider pre-hydration with IV fluids for children at high risk undergoing procedures involving contrast media.
  • Secondary Prevention: Early detection and intervention to prevent progression of AKI.
    • High-Risk Patient Monitoring: Close monitoring of urine output, fluid balance, and renal function (creatinine, electrolytes) in critically ill children, those with severe infections, cardiac conditions, or undergoing major surgery.
    • AKI Screening: Implement protocols for early recognition of AKI using validated definitions (e.g., KDIGO criteria) in hospitals.
  • Tertiary Prevention: Preventing complications and managing long-term sequelae of AKI.
    • Early Nephrology Consultation: For severe or persistent AKI.
    • Comprehensive Follow-up: Long-term follow-up for all children who have had AKI, especially severe episodes, to monitor for progression to CKD, hypertension, and other complications.
    • Patient and Family Education: On recognizing signs of renal dysfunction and adhering to follow-up plans.

Special Populations

  • Pediatric: The entire reference is focused on pediatric patients. Key considerations:
    • Neonates/Infants: Immature renal function, higher body water percentage, higher metabolic rate, limited ability to concentrate urine, increased risk of dehydration and electrolyte imbalances. Urine output definitions may differ slightly (e.g., <0.5 mL/kg/hr in critically ill neonates). Higher incidence of congenital anomalies.
    • Young Children: Difficulty verbalizing symptoms, reliance on parental observation of urine output and fluid intake.
    • Adolescents: May have adult-like causes of AKI (e.g., substance abuse, eating disorders leading to dehydration, sports injuries causing rhabdomyolysis).
    • Fluid Management: Careful calculations based on weight and body surface area, with precise monitoring.
    • Drug Dosing: Adjustment of nephrotoxic medications based on estimated GFR.
  • Comorbidities:
    • Congenital Heart Disease (CHD): Increased risk of AKI perioperatively, often requiring cautious fluid management to avoid fluid overload in the context of cardiac dysfunction.
    • Oncology Patients: At risk from tumor lysis syndrome, chemotherapy-induced nephrotoxicity, and complications of bone marrow transplantation.
    • Severe Burns: High fluid losses, risk of sepsis, rhabdomyolysis, and nephrotoxic drug use increase AKI risk.
    • Sickle Cell Disease: Prone to kidney injury due to vaso-occlusion and chronic kidney damage.

Clinical Pearls

  • Diagnostic:
    • "Urine output is the most sensitive and earliest clinical marker of AKI in children." A falling urine output often precedes a rise in serum creatinine.
    • "Always consider obstructive uropathy in any child with new-onset oliguria or anuria, particularly if there is a palpable bladder."
    • "FENa interpretation can be tricky: it's less reliable in neonates (due to immature tubules) and children on diuretics."
    • "A detailed medication history is crucial, as drug-induced AKI is a common and often reversible cause."
  • Treatment:
    • "The immediate goal is always to treat the underlying cause and optimize renal perfusion, unless there are signs of fluid overload."
    • "Fluid resuscitation must be balanced: too little leads to ongoing injury, too much causes severe complications like pulmonary edema."
    • "Hyperkalemia is a life-threatening emergency in AKI; treat it aggressively and monitor EKG."
    • "Early consultation with pediatric nephrology for persistent oliguria, severe electrolyte derangements, or need for RRT is essential."
  • Pitfalls:
    • "Delay in recognizing hypovolemia or obstruction."
    • "Over-reliance on serum creatinine, which is a lagging indicator of kidney injury."
    • "Excessive fluid administration in children who are not hypovolemic, leading to fluid overload and worse outcomes."
    • "Failure to recognize subtle signs of fluid overload or electrolyte disturbances."
    • "Inappropriate use or dosing of nephrotoxic drugs in a child with evolving AKI."

Recent Updates

  • Guidelines:
    • KDIGO (Kidney Disease: Improving Global Outcomes) 2012 AKI Guidelines: These remain the most widely accepted international guidelines for defining and staging AKI, and for management recommendations. Pediatric-specific modifications exist (e.g., pRIFLE, AKIN, and the integrated KDIGO definition for children).
    • NICE Guidelines (UK): Also provide comprehensive guidance on AKI recognition and management.
  • Evidence:
    • Novel Biomarkers: Ongoing research into the utility of novel biomarkers (e.g., NGAL, KIM-1, IL-18, urinary creatinine-adjusted biomarkers) for earlier and more precise diagnosis of AKI, though not yet routinely implemented in most clinical settings.
    • Fluid Management Strategies: Continued debate and research on optimal fluid resuscitation strategies in specific conditions like sepsis, with growing evidence emphasizing tailored fluid therapy rather than liberal administration. The Furosemide Stress Test (FST) has emerged as a potential tool to predict AKI reversibility and need for RRT.
    • Long-term Outcomes: Increasing focus on the long-term consequences of AKI in children, including progression to CKD and associated morbidities, highlighting the importance of post-AKI follow-up.
  • Controversies:
    • Optimal Fluid Resuscitation in Sepsis: Debate on the quantity and type of fluid (crystalloids vs. colloids, balanced vs. unbalanced solutions) in pediatric sepsis, especially in resource-limited settings.
    • Role of Diuretics: Optimal timing and dose of diuretics in established AKI; while often used for fluid overload, their role in improving renal outcomes remains debated.
    • Timing of RRT Initiation: While general indications for RRT are established, the precise optimal timing for initiation in children with AKI is still an area of ongoing research and clinical judgment.

Key References

  • Guidelines:
    • Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1-138. (Also available at kdigo.org)
    • NICE (National Institute for Health and Care Excellence) Clinical Guideline 169: Acute kidney injury: prevention, detection and management. (2013, updated 2023).
  • Studies:
    • Akcan-Arikan A, Zappitelli G, Loftis L, et al. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71(10):1028-35. (Original pRIFLE criteria)
    • Goldstein SL, Chawla LS, Daneshvar P, et al. AWARE Study Investigators. The Assessment of Worldwide Acute Kidney Injury, Renal Angina, and Epidemiology in Critically Ill Children (AWARE) Study: Design and Methods. Blood Purif. 2017;44(3):209-216.
  • Reviews:
    • Gomez H, Ince C, De Backer D, et al. Acute kidney injury in sepsis: science to application. Intensive Care Med. 2019;45(3):308-318.
    • Zappitelli M, Goldstein SL. Acute kidney injury in critically ill children. Pediatr Nephrol. 2016;31(11):2107-2121.
    • Basu RK, Zappitelli M. The Furosemide Stress Test in Pediatric Acute Kidney Injury. Pediatr Nephrol. 2017;32(11):2071-2079.

Dr. Vivek's AI | For Educational Purposes Only